| HRA005455
(Controlled Access)
|
Our team focused on the CRLM population receiving BVZ combined with chemotherapy as the first-line standard treatment, and initially explored the precision treatment of tumor resistance based on the genome and transcriptome sequencing of 49 matched samples obtained from multi-time nodes before and after treatment. Meanwhile, we demonstrate the underlying mechanisms of primary drug resistance mediated by SMAD4R361H missense mutations and secondary drug resistance under hepatocyte/myeloid cell interaction, which provided an analytical template and practical clinical basis for the accurate stratification as well as novel combined strategies of the first-line treatment in CRLM. |
